Spots Global Cancer Trial Database for Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
Official Title: A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase III Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy
Study ID: NCT01924533
Conditions
Study Description
Brief Summary: This study is a phase III, multi-centre study of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy. Patients will be from China, Japan , Korea and Taiwan.
Detailed Description: A randomized, double-blinded, multicentre phase III study to access the efficacy and safety of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in Asian patients with advanced gastric cancer (including gastro-oesophageal junction) who have progressed following first line therapy.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Beijing, , China
Research Site, Beijing, , China
Research Site, Beijing, , China
Research Site, Bengbu, , China
Research Site, Changchun, , China
Research Site, Changsha, , China
Research Site, Changsha, , China
Research Site, Changsha, , China
Research Site, Chengdu, , China
Research Site, Chengdu, , China
Research Site, Fuzhou, , China
Research Site, Guangzhou, , China
Research Site, Hangzhou, , China
Research Site, Hangzhou, , China
Research Site, Hangzhou, , China
Research Site, Harbin, , China
Research Site, Nanchang, , China
Research Site, Nanjing, , China
Research Site, Nanjing, , China
Research Site, Shanghai, , China
Research Site, Shanghai, , China
Research Site, Urumqi, , China
Research Site, Wanzhou, , China
Research Site, Wuhan, , China
Research Site, Yangzhou, , China
Research Site, Zhengzhou, , China
Research Site, Chiba-shi, , Japan
Research Site, Chuo-ku, , Japan
Research Site, Fukuoka-shi, , Japan
Research Site, Kasama-shi, , Japan
Research Site, Kawasaki-shi, , Japan
Research Site, Kitaadachi-gun, , Japan
Research Site, Koto-ku, , Japan
Research Site, Matsuyama-shi, , Japan
Research Site, Nagoya-shi, , Japan
Research Site, Sapporo-shi, , Japan
Research Site, Sapporo-shi, , Japan
Research Site, Takatsuki-shi, , Japan
Research Site, Utsunomiya-shi, , Japan
Research Site, Yokohama-shi, , Japan
Research Site, Anyang-si, , Korea, Republic of
Research Site, Daegu, , Korea, Republic of
Research Site, Hwasun-gun, , Korea, Republic of
Research Site, Jeonju-si, , Korea, Republic of
Research Site, Seongnam-si, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Kaohsiung Hsien, , Taiwan
Research Site, Taichung, , Taiwan
Research Site, Tainan, , Taiwan
Research Site, Taipei, , Taiwan
Research Site, Taoyuan, , Taiwan
Contact Details
Name: Yung-Jue Bang, MD
Affiliation: Seoul National University, College of Medicine and Cancer Research Institute, Republic of Korea
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
